Sexuality, Contraception, and Pregnancy in Kidney Transplantation

Krishna A. Agarwal and Martha Pavlakis

Sexual dysfunction is defined as any abnormality in sexual arousal, libido, intercourse, orgasm, or satisfaction. It is prevalent in patients with chronic and end-stage kidney disease, with 70% to 84% of men and 30% to 60% of women reporting some form of sexual dysfunction. Although kidney transplantation improves the overall quality of life for patients receiving dialysis, it can have unexpected effects on sexual function owing to the use of immunosuppressive medications and comorbid illnesses. It is important to recognize these adverse effects and pre-emptively discuss them with patients to help mitigate consequent psychosocial discontent. Women of reproductive age will often recover fertility after kidney transplantation and therefore need to be empowered to prevent unwanted pregnancies and plan for a safe pregnancy if desired. Complications such as preeclampsia, pregnancy-induced hypertension, gestational diabetes, ectopic pregnancy, still birth, low birth weight, and preterm birth are more common in pregnant women with a kidney transplant. Careful monitoring for infection, rejection, and immunosuppressive dose adjustment along with comanagement by a high-risk obstetrician is of utmost importance. Breast-feeding is safe with most immunosuppressive medications and should be encouraged.

SEXUAL FUNCTION IN KIDNEY FAILURE AND EARLIER STAGES OF CHRONIC KIDNEY DISEASE

Patients with chronic kidney disease (CKD) frequently have associated comorbid conditions such as diabetes, heart disease, and vasculopathies. Disorders in sexual function span both the physical and psychosocial domains. CKD and associated vasculopathies affect physical function but also have psychosocial effects through changes in hormonal balance, emotion, and socioeconomic burden. Sexual dysfunction can manifest as vaginal dryness or dyspareunia in women, erectile dysfunction or premature ejaculation in men, and decreased libido and inability to achieve an orgasm in both men and women.

A definitive assessment of the prevalence of sexual dysfunction in the CKD population is difficult because of the intimate nature of the topic, variable definitions, and lack of standardized registries for this data. Men with CKD have a reported prevalence of erectile dysfunction between 70% and 84%. Between 30% and 60% of women experience sexual dysfunction, higher in those receiving dialysis as compared with those with non-dialysis-dependent CKD. Women also tend to experience premature menopause, up to 4.5 years earlier, and infertility primarily owing to estrogen deficiency.

The sexual well-being of patients with CKD is under-recognized. It is neither regularly discussed by nephrologists nor reported in many “quality-of-life” trials. Moreover, patients referred for kidney transplantation often do not know what to expect after transplantation with respect to their sexual function.

SEXUAL FUNCTION POST–KIDNEY TRANSPLANTATION

Kidney transplantation is recognized as the gold-standard treatment for end-stage kidney disease, offering better quantity and quality of life as compared with dialysis. Sexual health is an important quality-of-life domain in these patients. Although kidney transplantation improves the hormonal and metabolic milieu in recipients, the physical effects of the transplantation surgery can distort one’s body image and hence affect sexual satisfaction. The emotional and psychological distress can reduce interest in sexual activities and/or result in erectile dysfunction in men and vaginal dryness in women. Decreased sexual satisfaction can impair overall quality of life and reduce life satisfaction. Immunosuppressive agents, particularly sirolimus, can impair sexual function.

Male Sexual Function After Transplantation

Libido, erectile function, orgasmic function, and sexual satisfaction are important components of male sexuality. A Dutch study reported a 48% prevalence of sexual problems in male kidney transplant recipients. This was lower than in patients receiving hemodialysis (HD; 62.9%) or peritoneal dialysis (69.8%) but greater than 5 times that in the control population (8.7%). The most commonly reported problems were erectile dysfunction (74%), decreased libido (41%), and orgasm concerns (29%). Similar results have been reported from France and Mexico. A recent study from Portugal explored sexual function and satisfaction in male kidney transplant recipients. Of the total 112 respondents, 66% had at least mild erectile dysfunction as measured by the International Index of Erectile Function (IIEF) score, 65% had desire dysfunction, 56% had orgasm dysfunction, and 76% had overall dissatisfaction with their sexual function. There was a significant negative correlation between body image satisfaction and sexual function, affecting recipients both within and more than 3 years after transplantation.
The effects of kidney transplantation on pre-existing sexual dysfunction are controversial. Previous studies have shown improvement in erectile dysfunction after kidney transplantation, but a recent study looked at both erectile and ejaculatory function prospectively in kidney transplant recipients. The mean IIEF score significantly decreased at 6 months and was unchanged at 12 months after transplantation. Ejaculatory function, as assessed by the Male Sexual Health Quality—Ejaculation Disorders (MSHQ-EjD) short form, also decreased significantly at the 6- and 12-month follow-up. Age, diabetes, hypertension, smoking, and pretransplantation testosterone levels were significantly associated with posttransplantation IIEF and MSHQ-EjD scores in addition to the baseline scores.

Most (72.8%) kidney transplant recipients studied by Meuhrer et al reported that sexuality was important. A total of 71% were sexually active and 80% had a regular sexual partner. Only 60% received information about posttransplantation sexuality from their health care providers and 64% of the patients who did not thought that they wanted the information. Unfortunately, less than half the patients who received the information were satisfied with it. The greatest areas of concern were communication with health care providers about sexuality and sexual pleasure. Women reported greater concerns than men.

**Female Sexual Function After Transplantation**

In the United States, 40% to 50% women of reproductive age have sexual concerns. Hypoactive sexual desire disorder is the most prevalent concern, followed by delayed orgasm and lack of orgasm. The literature on female sexual function in end-stage kidney disease and transplantation is scarce as compared with that on male sexual function. Several studies have reported a higher prevalence of sexual dysfunction in women receiving dialysis versus their counterparts without CKD, and sexual dysfunction was found in 94% of women receiving peritoneal dialysis and 100% of women receiving HD as compared with 45.8% of controls. A large study conducted in Europe and South America revealed an 84% prevalence of sexual dysfunction in women receiving HD, independently associated with age, depressive symptoms, lower education, menopause, diabetes, and diuretic therapy. Kurtulus et al reported sexual dysfunction in 56.7%, 89.7%, and 73.9% of the control, HD, and post-transplantation female patients, respectively.

The Female Sexual Function Index, a commonly used questionnaire to assess female sexual function, improved significantly in women with a kidney transplant, specifically the lubrication, pain, and total scores. Similarly, women with end-stage kidney disease followed up prospectively for 5 years posttransplantation had their mean Female Sexual Function Index score improve significantly from 17.57 ± 7.07 pretransplantation to 25.3 ± 3.28 posttransplantation, and depression scores decreased significantly from 17.91 ± 8.56 to 3 ± 4.17. Improvement in sexual function was seen in all domains including desire, arousal, lubrication, orgasm, satisfaction, and pain. These studies suggest that female sexual function may improve after kidney transplantation.

Female sexual desire and satisfaction were significantly better in living donor recipients when compared with deceased donor recipients, but they were also significantly younger (38.5 vs 51.5 years) and had shorter dialysis vintage (30.5 vs 44.5 months) than deceased donor recipients. Only 34.6% of women reported discussing sexual issues with their health care providers before transplantation, whereas 73% believed it would have been important.

**Special Considerations With Drugs**

In addition to immunosuppressive medications, transplant recipients are often receiving drugs for blood pressure, diabetes, electrolyte disorders, gastrointestinal symptoms, contraception, and mood disorders. Many of these drugs may independently affect sexual function and should be evaluated in patients presenting with sexual dysfunction. Table 1 summarizes some of these drugs and suggested alternatives.

**CONTRACEPTION**

Of the 23,301 kidney transplants performed in the United States in 2019, a total of 9,133 were in women, of which 3,474 (38%) were in the child-bearing ages (18-49 years) and 301 were younger than 17 years and could potentially be pregnant in the future. Ovulation and menstruation normalize within 6 to 9 months after transplantation and therefore fertility can return or increase. Studies show that pretransplantation contraception counseling is often inadequate. In Brazil, although 80% of female transplant recipients were sexually active and 72% were using a contraceptive, only 49% were counseled to use contraception. This group had an unintended pregnancy rate of 93%. In a report from Nebraska, 44% of female transplant recipients were unaware of pregnancy as a possibility after transplantation and only 43% of female recipients older than 13 years were counseled before transplantation about posttransplantation contraceptive use. Of these, only 50% had a specific method recommended and contraceptive pills were most commonly recommended (52%).

**Contraception Counseling**

Important considerations for contraception counseling:

1. Patient selection: all kidney transplant recipients with child-bearing potential, current or future.
2. Counseling should begin at the time of transplantation evaluation and continue into the posttransplantation period.
3. Patients’ own understanding of their sexuality, values, and beliefs about contraception and plan for pregnancy should be explored.
4. All contraceptive methods should be offered and risks and benefits discussed. The choice of contraception would depend on patients’ preferences and safety.
| Drug | Sexual Side Effect | Management |
|------|-------------------|------------|
| **Immunosuppressive Agents** | | |
| Belatacept | No direct effect. | Can consider alternatives if severe side effects outweigh benefits; alternatively, use sexual enhancers |
| Tacrolimus, cyclosporine | No direct effect; depression, weakness | Can consider alternatives if severe side effects outweigh benefits; alternatively, use sexual enhancers |
| Sirolimus, everolimus | Decreased sexual desire and erectile dysfunction in men; decreases testosterone levels | Can consider alternatives if severe side effects outweigh benefits; alternatively, use sexual enhancers |
| Mycophenolate mofetil | Erectile dysfunction in men; teratogenic | Can consider alternatives if severe side effects outweigh benefits; alternatively, use sexual enhancers |
| Azathioprine | No direct effect | |
| Steroids | Decreased testosterone; erectile dysfunction in men; menstrual irregularities in women | Steroid-sparing regimens when possible or lowest possible dose; alternatively, use sexual enhancers |
| **Antihypertensive Agents** | | |
| Thiazide diuretics | Decreased libido, erectile dysfunction, and decreased ejaculation in men | Switch to loop diuretic; consider sexual enhancer |
| Potassium-sparing diuretics | Decreased libido, erectile dysfunction, and decreased ejaculation in men | Switch to loop diuretic; consider sexual enhancer |
| β-Blockers | Decreased sexual desire in men and women; erectile dysfunction in men | Consider alternative antihypertensive agents; use caution with PDE5 inhibitors in patients on antihypertensives, especially nitrates |
| Centrally acting α-agonist | Decreased sexual desire in men and women; erectile dysfunction in men | Consider alternative antihypertensive agents; use caution with PDE5 inhibitors in patients on antihypertensives, especially nitrates |
| α-Receptor blockers | May rarely decrease sexual desire in men and women | Consider using PDE5 inhibitors in combination with α-blockers and/or ARI when used for lower urinary tract symptoms in men25 |
| α-reductase inhibitors (ARI) | Decreased libido, erectile dysfunction, and decreased ejaculation in men | Consider using PDE5 inhibitors in combination with α-blockers and/or ARI when used for lower urinary tract symptoms in men25 |
| Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers | No direct effects; extremely rare incidence of erectile dysfunction in men; teratogenic | Consider alternative antihypertensive agents; sexual enhancers |
| Calcium channel blockers | Rare; decreased libido in men and women; decreased penile tumescence, decreased ejaculation, and gynecomastia; galactorrhea in women | Consider alternative antihypertensive agents; sexual enhancers |
| **Antihistamines** | | |
| Diphenhydramine, cetirizine, loratadine | Inhibited sexual arousal, vaginal dryness; erectile dysfunction | Consider timing medication away from sexual activity; use OTC lubricants for dryness |
| **H₂-Blockers** | | |
| Cimetidine | Decreased libido, erectile dysfunction, and decreased sperm count | Use alternative agents like famotidine or ranitidine |
| **Antidepressants** | | |
| SSRIs, eg, fluoxetine, paroxetine, sertraline | Decreased libido, erectile dysfunction; delayed orgasm; decreased sexual satisfaction | Consider alternative agents like bupropion, mirtazapine, vortioxetine; reduce dose of SSRI or consider drug holiday and/or addition of sex-enhancing drugs like sildenafil or tadalafil |

(Continued)
profiles based on other medical comorbid conditions and graft status.

5. Implications of unintended pregnancy while receiving immunosuppressive agents should be discussed, including teratogenicity associated with mycophenolate.

6. If patient intends to become pregnant, preconception counseling is essential to avoid adverse outcomes for the kidney transplant, the patient, and the child, and multidisciplinary care should be initiated as discussed later.

Methods of Contraception

The World Health Organization published guidelines (Medical Eligibility Criteria for Contraceptive Use) for contraceptive use in women with specific comorbid conditions. In the United States, the Centers for Disease Control and Prevention adapted and issued guidelines.

Methods of Contraception

| Drug                                      | Sexual Side Effect                              | Management                                                                 |
|-------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------|
| SNRIs, eg, venlafaxine, desvenlafaxine, duloxetine | Decreased libido, erectile dysfunction; delayed orgasm; decreased sexual satisfaction | Consider alternative agents like bupropion, mirtazapine, vortioxetine; reduce dose of SSRI or consider drug holiday and/or addition of sex-enhancing drugs like sildenafil or tadalafil |
| Monoamine oxidase inhibitors, eg, isocarboxazid, phenelzine, selegiline, tranylcypromine (used infrequently) | Decreased libido, erectile dysfunction; delayed orgasm; decreased sexual satisfaction | Consider alternative agents like bupropion, mirtazapine, vortioxetine; reduce dose of SSRI or consider drug holiday and/or addition of sex enhancing drugs like sildenafil or tadalafil |
| Tricyclic antidepressants, eg, amitriptyline, nortriptyline, clomipramine, doxepin | Decreased libido, erectile dysfunction; delayed orgasm; decreased sexual satisfaction | Consider alternative agents like bupropion, mirtazapine, vortioxetine; reduce dose of SSRI or consider drug holiday and/or addition of sex enhancing drugs like sildenafil or tadalafil |

Antipsychotics

| Drug                                      | Sexual Side Effect                              | Management                                                                 |
|-------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------|
| Prolactin-elevating agents, eg, haloperidol, risperidone, amisulpride | Decreased libido, impaired arousal, and impaired orgasm; may also cause erectile dysfunction, delayed ejaculation in men; poor vaginal lubrication in women | Decreased dose or switch to alternate agent (prolactin-sparing) and/or addition of sex-enhancing drugs |
| Prolactin-sparing agents, eg, olanzapine, clozapine, quetiapine, aripiprazole | Same as above but much lesser frequency and severity | Decreased dose or switch to alternate agent (prolactin-sparing) and/or addition of sex enhancing drugs |

Antianxiety Agents

| Drug                                      | Sexual Side Effect                              | Management                                                                 |
|-------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------|
| Lorazepam, diazepam | Decreased arousal, libido, and delayed orgasm | Cognitive behavioral therapy; decreased dose and/or addition of sex enhancing drugs |

Hormonal Birth Control

| Drug                                      | Sexual Side Effect                              | Management                                                                 |
|-------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------|
| Combined contraceptive pills, progestin-only pills, depo-MPA | Decreased arousal and libido | Use nonhormonal methods like barriers or vaginal ring |

Abbreviations: ARI, 5α-reductase inhibitors; depo-MPA, depo medroxyprogesterone acetate; OTC, over-the-counter; PDE5, phosphodiesterase type 5; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
uterus during a short office procedure. Rare risks include pelvic inflammatory disease and uterine wall perforation. Levonorgestrel IUD (eg, Mirena, Bayer). A small amount of progestin is released and makes the intrauterine milieu unsuitable for implantation. This device is safe, effective, long lasting, and reversible and does not have any significant interaction with immunosuppressive medications or systemic effects. Impressively, failure rates range from 0.1% to 0.4%. Recent case series in organ transplant recipients have quelled previous concerns and established the safety and efficacy of the levonorgestrel IUD in these patients.

**Copper T**
The Copper-T is nonhormonal but shares the same benefits as a progestin-based IUD and can be used for up to 10 years. The failure rate is 0.8%.

**Progestin-Based Implant (etinogestrel)**
A thin rod is inserted under the skin in the upper arm. It slowly releases progestin for up to 3 years. The benefits include decreased menstrual blood losses and protection against endometrial cancer. There is a risk for abnormal uterine bleeding, headaches, and weight gain. The etinogestrel implant (Nexplanon, Organon) is considered the most effective progestin-only contraceptive method. The typical failure rate is 0.1%.

**Progestin-Based Injection (depot medroxyprogesterone)**
This injection in the buttock or arm needs to be repeated every 3 months. Benefits are similar to progestin implants but risks include decreased bone mineral density in addition to abnormal uterine bleeding, headaches, and weight gain. The failure rate is up to 4%, commonly due to delay in repeat injections.

**Progestin-Only Pill**
Also known as the “mini-pill,” this pill has only a single hormone, progestin. It needs to be taken at the same time every day and is better for women with contraindications to the estrogen component of combined contraceptives. Side effects include abnormal bleeding, headaches, and weight gain. The typical failure rate is 7%.

**Combined Hormonal Contraceptives**
These contraceptives include pills, patches, or vaginal rings. They release both estrogen and progestin hormones and can reduce uterine bleeding, dysmenorrhea, acne, hirsutism, and risks for ovarian and endometrial cancer. Risks include venous thromboembolism, hypertension, stroke, and heart attacks. These risks are greater in tobacco smokers, women older than 35 years, and those with a family history of blood clots. The typical failure rate is 7%.

---

**Female Barrier Methods**
Female condom (failure rate, 21%), diaphragm, or cervical cap (failure rate, 17%) and vaginal sponge with spermicide (failure rate, 14%-27%) are types of female barrier methods. Risks include sepsis and toxic shock syndrome if left for longer periods. A major benefit of barrier methods is protection against sexually transmitted diseases.

**Male Condom**
A condom needs to be used consistently by the male partner to prevent unintended pregnancies. The failure rate with typical use is 13%, and like female barrier methods, these also provide protection against sexually transmitted diseases.

**Spermicides**
Spermicides are chemicals that kill sperm in the female reproductive tract. They can be in the form of gels, creams, foam, suppository, tablet, or film. Ideally, spermicides should be used in conjunction with barrier methods. The typical failure rate for spermicides is 21%. Risks include local vaginal irritation and/or allergic reactions.

The least effective methods include withdrawal, fertility awareness–based methods (failure rate, 2%-23%), and lactational amenorrhea.

**Contraception Guidance for Mycophenolate Exposure**
Given the increased risk for first-trimester pregnancy loss and congenital malformations associated with mycophenolate exposure, the US Food and Drug Administration (FDA) requires a Risk Evaluation and Mitigation Strategy (REMS). As part of mycophenolate REMS, female kidney transplant recipients have 3 acceptable options for contraception use, as follows: option 1, standalone use of IUD or tubal ligation; option 2, one hormonal and 1 barrier method; and option 3, two barrier methods (male or female condom and female diaphragm or cervical cap with spermicide or a contraceptive sponge).

---

**MANAGEMENT OF POSTTRANSPLANTATION PREGNANCY**
The first successful pregnancy in a kidney transplant recipient was reported in 1958. The delivering team opted for elective caesarean section for fear of damage to the allograft from fetal vertex. Since then, more than 14,000 pregnancies in kidney transplant recipients have been documented in the literature. Most of the data about pregnancies in the transplant population are available through case reports, single-center case series, and voluntary registries such as the Transplant Pregnancy Registry International (TPRI, formerly National Transplant Pregnancy Registry) and the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA).
Physiologic Changes During Pregnancy
An increase in cardiac output and blood volume and decrease in systemic vascular resistance lead to an increased glomerular filtration rate and decreased serum creatinine level. In pregnant women who have undergone transplantation, glomerular filtration rate can increase by up to 34% in the first trimester and returns to prepregnancy levels by the third semester. Urinary protein levels increase during pregnancy and can exceed 500 mg/24 h by the third trimester before returning to normal within 3 months postpartum. Other common causes of proteinuria include urinary tract infections and preeclampsia.

Preconception Counseling
The first question that prepartum transplant recipients and their health care providers face is regarding the timing of pregnancy. When is it safe to become pregnant? In 2005, the American Society of Transplantation published their report on the Consensus Conference of Reproductive Issues and Transplantation. The consensus statement advised a transplantation-to-conception interval of at least 1 year. The timing of pregnancy should be individualized based on risk for rejection, fetotoxic infections such as cytomegalovirus, concomitant use of teratogenic medications, and overall graft function. Conception is considered safe with no rejection in the past year, adequate stable graft function (creatinine < 1.5 mg/dL), no or minimal proteinuria, no fetotoxic infections, and a stable immunosuppressive regimen.

A recent study using Medicare claims from the US Renal Data System reported the probability of kidney graft failure from any cause (including death) as 9.6%, 25.9%, and 36.6% at 1, 3, and 5 years after pregnancy. Women who became pregnant in the first 2 posttransplant years had higher risk for death-censored graft loss as compared with their nonpregnant counterparts (hazard ratio, 1.25 in year 1 and 1.26 in year 2); pregnancy in posttransplantation year 3 was not associated with increased risk for graft failure. Pregnancy in a transplant recipient is considered high risk and therefore should be managed in consultation with a high-risk obstetrician if available. The goal is to maintain stable allograft function, allow for a normal metabolic milieu, and avoid complications such as preeclampsia, eclampsia, preterm birth, fetal growth restriction, and intrauterine fetal demise.

Our approach to preconception counseling is as follows:

- Begin before transplantation and carry discussions into the posttransplantation period
- Discuss the timing of pregnancy based on individual factors as described previously
- Discuss data on pregnancy outcomes and set realistic expectations
- Encourage partner participation throughout counseling
- Refer to a high-risk obstetrician

- Medication management: for patients receiving mycophenolate, we check for donor-specific antibodies before stopping mycophenolate therapy and recommend contraception for 6 weeks after switching from mycophenolate to azathioprine. If there is no concern for rejection during these 6 weeks, conception can be attempted
- Address the need for postpartum birth control and discuss spacing between pregnancies as appropriate

Pregnancy Outcomes and Complications
An international study evaluated 6,712 pregnancies in 4,174 kidney transplant recipients with a mean maternal age of 29.6 ± 2.4 years and mean transplantation-to-conception interval of 3.7 years. Overall, pregnancies in kidney transplant recipients appeared to be safe with acceptable maternal, fetal, and graft outcomes. The live birth rate (72.9%) is comparable to that in the general US population. The following complications in pregnant transplant recipients are higher than in the general US population: stillbirth rate (5.1% vs 0.6%), ectopic pregnancies (2.4% vs 1.4%), preeclampsia (21.5% vs 3.8%), pregnancy-induced hypertension (24.1% vs 5-9%), gestational diabetes (5.7% vs 2%-10%), and cesarean section delivery (62.6% vs 31.9%). Preterm birth (48%) and low birth weight (53%) were significantly higher in kidney transplant recipients than in the general population. Acute kidney rejection occurred in 9.4% during pregnancy as compared with 9.1% in the US nonpregnant transplant population, and 9.2% of women lost their graft in the first 2 years following delivery. Creatinine level showed a small but significant elevation after pregnancy, from 1.23 ± 0.16 to 1.37 ± 0.27 mg/dL. A transplantation-to-conception interval of 2 to 3 years was unfavorable as compared with less than 2 or more than 3 years in terms of spontaneous abortion, neonatal deaths, cesarean section, live birth rate, and preeclampsia. Creatinine level > 1.3 mg/dL, proteinuria with protein excretion > 500 mg per day, diastolic blood pressure > 90 mm Hg, and more than 1 kidney transplant were associated with poor pregnancy outcomes.

Acute Rejection During Pregnancy
Acute kidney rejection can occur in pregnancy with rates similar to that in the nonpregnant population. Patients with elevated prepregnancy creatinine levels and fluctuating immunosuppressive drug levels are at higher risk for rejection. Preeclampsia and acute pyelonephritis are important differentials. If rejection is suspected, an ultrasound-guided kidney biopsy should be performed. When rejection is confirmed, corticosteroids are preferred in addition to augmentation of baseline immunosuppression. Data with intravenous immunoglobulin, antithymocyte globulin, plasma exchange, and rituximab are sparse.
Urinary Tract Infections During Pregnancy
Asymptomatic bacteriuria can be seen in 2% to 15% of uncomplicated pregnancies and more so in transplant recipients. If untreated, up to 30% can progress to acute pyelonephritis. Given the anatomy of the transplanted ureter, this risk is significantly higher in transplant recipients. Therefore, we recommend screening for asymptomatic bacteriuria with urinalysis every 2 to 4 weeks and treating with antibiotics based on culture results if infection is present.

Immunosuppressive Drug Management During Pregnancy
Calcineurin Inhibitors
Calcineurin inhibitors are considered safe for the mother and fetus during pregnancy and should be continued throughout pregnancy. Calcineurin inhibitor blood levels may fluctuate due to the physiologic expansion of blood volume, changes in intestinal motility, changes in metabolic enzyme activity, and gastrointestinal losses with vomiting (Table 3). A 20% to 25% dose increase may be

---

### Table 2. Contraceptive Methods

| Method                        | Pros                                   | Risks                                         | Failure Rate |
|-------------------------------|----------------------------------------|-----------------------------------------------|--------------|
| **Permanent Sterilization**   |                                        |                                               |              |
| Female tubal ligation         | Single, 1-time procedure               | Risk for infection, bleeding, tubal ectopic   | <1%          |
|                               |                                        | pregnancy                                     |              |
| Male vasectomy                | Single, 1-time procedure               | Risk due infection, bleeding,                 | <1%          |
|                               |                                        | Waiting period before efficacy                |              |
| **IUDs**                      |                                        |                                               |              |
| Levonorgestrel IUD            | Long-lasting (up to 5 y), reversible   | Irregular bleeding, pelvic pain               | 0.1%-0.4%    |
| Copper-containing IUD         | Long-lasting (up to 10 y), reversible  | Pelvic inflammatory disease, bleeding,        | 0.8%         |
|                               |                                        | uterine perforation                           |              |
| Hormonal implant (etonogestrel-based) | Lasts up to 3 y, easy insertion, decreased bleeding | Weight gain, abnormal uterine bleeding, breast tenderness | 0.1%         |
| Depot medroxyprogesterone     | Decreased bleeding                     | Needs to be injected every 3 mo, decreased    | 4%           |
|                               |                                        | bone mineral density, abnormal uterine       |              |
|                               |                                        | bleeding, weight gain, headaches              |              |

**Oral Contraceptives**

| Method                                   | Pros                                      | Risks                                           | Failure Rate |
|------------------------------------------|-------------------------------------------|-------------------------------------------------|--------------|
| Progestin-only pill                       | No estrogenic side effects                | Irregular bleeding, headaches, breast tenderness, nausea | 7%           |
| Combined contraceptive pill              | Regulate menstrual cycle, predictable bleeding, reduction of dysmenorrhea, acne, hirsutism, Decreased ovarian and endometrial cancer risk | Estrogenic thrombotic risks including VTE, stroke, MI | 7%           |

**Vaginal or Exterior Contraceptives**

| Method                         | Pros                                         | Risks                                           | Failure Rate |
|-------------------------------|----------------------------------------------|-------------------------------------------------|--------------|
| Vaginal ring                  | Can self-insert and remove when desired      | Irritation, bleeding, risk for infection         | 7%           |
| Combined contraceptive patch | Self-administration                           | Higher estrogen exposure than other hormonal methods; VTE, hypertension, stroke, MI | 7%           |

**Barrier Methods**

| Method                           | Pros                                   | Risks                                                | Failure Rate |
|----------------------------------|----------------------------------------|------------------------------------------------------|--------------|
| Female condom                    | Ease of use, self-insertion            | Irritation, allergic reaction, sepsis, and toxic shock | 21%          |
| Diaphragm or cervical cap        | Ease of use, self-insertion            | Irritation, allergic reaction, sepsis, and toxic shock | 17%          |
| Vaginal sponge with spermicide   | Ease of use, self-insertion            | Irritation, allergic reaction, sepsis, and toxic shock | 14%-27%      |
| Male condom                      | Protection against STIs                 | Allergic reaction                                   | 13%          |
| Spermicides                      | Can be used in combination with other methods | Allergic reaction, irritation                       | 21%          |

Abbreviations: IUD, intrauterine device; MI, myocardial infarction; STI, sexually transmitted infection; VTE, venous thromboembolism.
required to maintain therapeutic levels. Tacrolimus circulates in unbound and bound form to albumin and white and red blood cells. Therefore, titrating dose to whole-blood tacrolimus levels can increase the free tacrolimus level and cause drug toxicity in women with low albumin levels and blood cell counts. Plasma tacrolimus levels may better reflect therapeutic levels (free unbound drug concentration) but are not generally available in clinical practice. Tacrolimus crosses the placenta and can cause reversible nephrotoxicity and hyperkalemia in the fetus, but placental P-glycoprotein lowers fetal exposure by active efflux of tacrolimus back into the maternal circulation.

MycopHENOLIC ACID AND MYCOPHENOLATE MOFETIL
Mycophenolic acid (MPA) and mycophenolate mofetil (MMF) are contraindicated in pregnancy and must be stopped at least 6 weeks before conception. This is based on the black box warning issued by the FDA when it changed its pregnancy category for MPA/MMF from C to D in 2007. MPA and MMF products are associated with increased risk for spontaneous abortions and structural birth defects such as hypoplastic nails, shortened fifth digit, microtia, and cleft lip and palate. This risk has not been observed when MPA/MMF are taken by the father. As part of the program, all women of reproductive age should receive a urine pregnancy test immediately before initiating MPA/MMF treatment and again in 8 to 10 days. They should be counseled about the risks of pregnancy with MPA/MMF and the importance of using acceptable contraception (described previously) during and for 6 weeks after stopping MPA treatment. As per the 2019 Annual Report of TPRI, there are 142 reported pregnancies with MPA exposure. In these, the live birth rate was 48% as compared with 78% in the group that stopped MPA treatment 6 weeks before conception (n = 302) and miscarriages occurred in 48% versus 20%. There was no significant difference in mean gestational age, prematurity, mean birth weight, or birth defects, although 11.6% of pregnancies with MPA exposure resulted in birth defects as compared with 5.7% without exposure.

**Azathioprine**
Azathioprine is considered safe in pregnancy and is the alternative of choice for patients receiving MPA/MMF. The fetal liver does not convert azathioprine to its active metabolite and hence teratogenicity is usually not seen. Complete blood cell counts and liver chemistry test results should be monitored in the mother and dose should be adjusted accordingly.

**Corticosteroids**
Low-dose corticosteroids used in maintenance immunosuppression have not been associated with adverse fetal

### Table 3. Various Agents Used for Maintenance Immunosuppression in Kidney Transplant Recipients and Special Considerations During Pregnancy and Breastfeeding

| Immunosuppressive Agent | Monitoring | Special Considerations With Pregnancy | Special Considerations With Breast-feeding |
|-------------------------|------------|--------------------------------------|------------------------------------------|
| Calcineurin-inhibitors (tacrolimus, cyclosporine) | Blood trough level every 2-4 wk | Expansion of blood volume, changes in intestinal motility and increased metabolic enzyme activity may necessitate 20%-25% dose increase | Breast-feeding is safe; <1% maternal weight-adjusted dose exposure to infant through breast milk |
| Mycophenolate compounds | Blood cell counts for cytopenias | Must be stopped at least 6 wk before conception; Mycophenolate REMS program | Known teratogen; breast-feeding not recommended if mycophenolate is being used |
| Azathioprine | Blood cell counts and liver enzymes | Safe alternative to mycophenolate | Breast-feeding is safe |
| Corticosteroids | Blood glucose, blood pressure | Low doses used for maintenance are not associated with adverse fetal effects | Breast-feeding is safe; infant only receives 0.1% of maternal dose through breast milk |
| Sirolimus | Blood trough levels every 2-4 wk | Fetal defects seen in animal studies; sirolimus should be stopped 6-12 wk preconception if possible | Breast-feeding not recommended due to delayed wound healing and lack of evidence demonstrating safety |
| Everolimus | Blood trough levels every 2-4 wk | Sparse data | Breast-feeding not recommended due to delayed wound healing and lack of evidence demonstrating safety |
| Belatacept | Blood cell counts and electrolytes every 4 wk | Only few case reports of pregnancy with belatacept | Data are lacking |
effects. Breast-fed infants have minimal exposure to prednisone and therefore breast-feeding is considered safe with prednisone use.

**Sirolimus and Everolimus**

Sirolimus exposure during pregnancy has not been associated with significantly different outcomes than pregnancies without sirolimus exposure. As per TPRI, 74% of pregnancies with sirolimus exposure resulted in live births and 24% had miscarriages. However, given the structural defects seen in animal studies, many centers choose to stop sirolimus treatment 6 to 12 weeks preconception and switch to azathioprine. Data about everolimus exposure are sparse, with 71% of 6 reported pregnancies resulting in live births.

**Belatacept**

Belatacept is a newer immunosuppressive agent that selectively blocks the costimulatory pathway in T-cell activation. There are only a few case reports of pregnancy with belatacept exposure; 2 successful pregnancies in kidney transplant recipients and 1 in a liver transplant recipient.

**Breast-feeding**

The American Academy of Pediatrics recommends exclusive breast-feeding for 6 months, followed by gradual introduction of complimentary foods. There are no definite guidelines on breast-feeding with immunosuppressive medications but the TPRI has not received any reports of adverse effects in breast-fed infants whose mothers were receiving prednisone, azathioprine, cyclosporine, and tacrolimus. MPA is a known teratogen and sirolimus/everolimus are associated with decreased wound healing. Therefore, breast-feeding with these agents is not recommended due to theoretical concerns and limited data. Infant exposure to drugs through breast milk is far less than in utero. For example, tacrolimus concentrations in umbilical blood can reach 71% of maternal whole blood concentrations but <1% of maternal weight-adjusted dose in breast milk. Similarly, prednisolone exposure through breast milk is 0.1% of maternal dose, which is <10% of the infant’s endogenous corticosteroid production. Given the higher prevalence of preterm birth and low birth weight in transplant recipients, breast-feeding assumes a greater therapeutic role. Breast milk reduces the risk for infections and necrotizing enterocolitis and can increase mental, motor, and behavioral development at ages 18 and 30 months in preterm infants.

The benefits of breast-feeding generally outweigh the risks to the infant and therefore we encourage breast-feeding among our transplant recipients. During the past 3 decades, there has been a modest increase in transplant recipients breast-feeding their infants as per the TPRI report.

**CONCLUSIONS**

Sexual dysfunction is common in patients with kidney failure and earlier stages of CKD. Kidney transplantation improves overall sexual function and fertility. Women of reproductive potential can regain fertility after transplantation and therefore need to be empowered to plan for a pregnancy that is safe for the fetus and mother, as well as the kidney graft. Counseling should start at the time of transplantation evaluation and carry into the post-transplantation period. Breast-feeding is safe and should be encouraged.

**REFERENCES**

1. Fiuk JV, Tadros NN. Erectile dysfunction in renal failure and transplant patients. Transl Androl Urol. 2019;8(2):155-163.
2. Anantharaman P, Schmidt RJ. Sexual function in chronic kidney disease. Adv Chronic Kidney Dis. 2007;14(2):119-125.
3. Navaneethan SD, Vecchio M, Johnson DW, et al. Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis. 2010;56(4):670-685.
4. Esen B, Kahvecioglu S, Atay AE, et al. Evaluation of relationship between sexual functions, depression and quality of life in patients with chronic kidney disease at predialysis stage. Ren Fail. 2015;37(2):262-267.
5. Holley JL. The hypothalamic-pituitary axis in men and women with chronic kidney disease. Adv Chronic Kidney Dis. 2004;11(4):337-341.
6. Harrison TG, Skr tic M, Verdin NE, Lanktree MB, Elliott MJ. Improving sexual function in people with chronic kidney disease: a narrative review of an unmet need in nephrology research. Can J Kidney Health Dis. 2020;7:2054358120952202.
7. Matas AJ, Halbert RJ, Barr ML, et al. Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. Clin Transplant. 2002;16(2):119-121.
8. Muehrer RJ. Sexuality, an important component of the quality of life of the kidney transplant recipient. Transplant Rev. 2009;23(4):214-223.
9. Espinoza R, Gracida C, Cancino J, Ibarra A. Prevalence of erectile dysfunction in kidney transplant recipients. Transplant Proc. 2006;38(3):916-917.

10. Burra P. Sexual dysfunction after liver transplantation. Liver Transplant. 2009;15(suppl 2):S50-S56.

11. Diemont WL, Vruggink PA, Meuleman EJH, Doesburg WH, Lemmens WAJG, Berden JHM. Sexual dysfunction after renal replacement therapy. Am J Kidney Dis. 2000;35(5):845-851.

12. Malavaud B, Rostaing L, Rischmann P, Sarramon JP, Durand D. Sexual function and fertility awareness among women with solid organ transplants. Obstet Gynecol. 2013;122(4):809-814.

13. Mota RL, Fonseca R, Santos JC, et al. Sexual dysfunction and its management. J Sex Med. 2010;7(12):3963-3968.

14. Cabral JF, Cavadas V, Silva Ramos M, et al. Female sexual function and depression after kidney transplantation: comparison between deceased- and living-donor recipients. Transplant Proc. 2015;47(4):989-991.

20. Yazici R, Altintepe L, Guney I, et al. Sexual dysfunction and satisfaction in kidney transplant patients. J Sex Med. 2019;16(7):1018-1028.

21. Strippoli GFM. Sexual dysfunction in women with ESRD. Clin J Am Soc Nephrol. 2012;7(6):974-981.

22. Kurtulus FO, Salman MY, Fazlioglu A, Fazlioglu B. Effects of Kettas¸ E, Çayan F, Efesoy O, Akbay E, Çayan S. The effect of pregnancy on kidney function in renal transplantation on female sexual dysfunction: comparative study with hemodialysis and a control group. J Sex Med. 2010;7(12):3963-3968.

23. Malavaud B, Rostaing L, Rischmann P, Sarramon JP, Durand D. Sexual function and fertility awareness among women with solid organ transplants. Obstet Gynecol. 2013;122(4):809-814.

24. Cabral JF, Cavadas V, Silva Ramos M, et al. Female sexual function and depression after kidney transplantation: comparison between deceased- and living-donor recipients. Transplant Proc. 2015;47(4):989-991.

25. La Torre A, Giupponi G, Duffy D, Conca A, Cai T, Scardigli A. Sexual dysfunction related to drugs: a critical review. Part V: α-blocker and 5-ARI drugs. Pharmacopsychiatry. 2016;49(1):3-13.

26. Park YW, Kim Y, Lee JH. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health. 2012;30(3):153.

27. National Database of the Organ Procurement & Transplantation Network. OPTN Database. Published 2019. Accessed September 1, 2021. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/

28. Richman K, Goh R. Pregnancy after renal transplantation: a review of registry and single-center practices and outcomes. Nephrol Dial Transplant. 2012;27(9):3428-3434.
transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698-1702.

50. Jones A, Clary M, McDermott E, et al. Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products. Prog Transplant. 2013;23(2):153-157.

51. Mycophenolate REMS. Accessed January 16, 2021. https://www.mycophenolate_rems.com/

52. Gonzalez Suarez ML, Parker AS, Cheungpasitporn W. Pregnancy in kidney transplant recipients. Adv Chronic Kidney Dis. 2020;27(6):486-498.

53. Tegethoff M, Pryce C, Meinlschmidt G. Effects of intrauterine exposure to synthetic glucocorticoids on fetal, newborn, and infant hypothalamic-pituitary-adrenal axis function in humans: a systematic review. Endocr Rev. 2009;30(7):753-789.

54. Constantinescu S, Pai A, Coscia LA, Davison JM, Moritz MJ, Armenti VT. Breast-feeding after transplantation. Best Pract Res Clin Obstet Gynaecol. 2014;28(8):1163-1173.

55. Combs J, Kagan A, Boelkins M, Coscia L, Moritz M, Hofmann RM. Belatacept during pregnancy in renal transplant recipients: two case reports. Am J Transplant. 2018;18(8):2079-2082.

56. Klintmalm GB, Gunby RT. Successful pregnancy in a liver transplant recipient on belatacept. Liver Transplant. 2020;26(9):1193-1194.

57. Tacrolimus - Drugs and Lactation Database (LactMed). NCBI Bookshelf. Accessed February 5, 2021. https://www.ncbi.nlm.nih.gov/books/NBK501104/

58. Sullivan S, Schanler RJ, Kim JH, et al. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. J Pediatr. 2010;156(4):S62-S67.e1.

59. Vohr BR, Poindexter BB, Dusick AM, et al. Beneficial effects of breast milk in the neonatal intensive care unit on the developmental outcome of extremely low birth weight infants at 18 months of age. Pediatrics. 2006;118(1):e115-e123.

60. Vohr BR, Poindexter BB, Dusick AM, et al. Persistent beneficial effects of breast milk ingested in the neonatal intensive care unit on outcomes of extremely low birth weight infants at 30 months of age. Pediatrics. 2007;120(4):e953-e959.